Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 13/20 | 0.54 |
| ▸ | GRM5 | P41594 | 5/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3004620 | 1.00 | NPY5R (0.54) | NPY5RGRM5HSD11B1OPRM1OPRL1 | |
| SCHEMBL3004622 | 1.00 | NPY5R (0.54) | NPY5RGRM5HSD11B1OPRM1OPRL1 | |
| Lithium Ion SCHEMBL2999452 | 0.89 | NPY5R (0.52) | NPY5RGRM5 | |
| Lithium Ion SCHEMBL2999454 | 0.89 | NPY5R (0.52) | NPY5RGRM5 | |
| SCHEMBL3012961 | 0.85 | NPY5R (0.55) | NPY5RGRM5OPRM1 | |
| SCHEMBL3743798 | 0.85 | NPY5R (0.55) | NPY5RGRM5OPRM1 | |
| SCHEMBL3012959 | 0.85 | NPY5R (0.55) | NPY5RGRM5OPRM1 | |
| SCHEMBL13045661 | 0.84 | NPY5R (0.52) | NPY5RGRM5HSD11B1 | |
| SCHEMBL3741649 | 0.84 | NPY5R (0.61) | NPY5RGRM5 | |
| SCHEMBL3741651 | 0.84 | NPY5R (0.61) | NPY5RGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286151-A1 | 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders | BENTLEY JONATHAN | 2010-11-11 | — | — | US | disclosed |
| EP-2118097-A1 | 1-OXA-3-AZASPIRO[4,5]DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | disclosed |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| WO-2009095377-A1 | SPIRO COMPOUNDS AS NPY Y5 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | WO | disclosed |
| US-20090042897-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| WO-2008092888-A1 | 1-OXA-3-AZASPIRO[4,5]DECAN--2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092891-A1 | 1-OXA-3-AZASPIRO(4.5)DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | NPY4R, NPY1R, NPY5R | NPY5R 3/4885GRM5 332/4885HSD11B1 404/4885 |
| US-20090042897-A1 | Chemical Compounds | NPY5R, NPY1R, NPY2R | NPY5R 1/4885GRM5 25/4885HSD11B1 1243/4885 |
| US-20100286151-A1 | 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders | NPY5R, NPY1R, NPY4R | NPY5R 1/4885GRM5 176/4885HSD11B1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.